If you notice any issues or missing content, please let us know. Your feedback helps us improve. Thank you.
Principal Investigator
Dr. Gautam Singhvi
Funding Agency
Slyback Pharma
Type of Project
Industry
Sanction Amount (INR)
14
End Date
29/03/2022
Status
Completed
Nanotechnology based pharmaceutical, nutraceuticals and cosmetics-development of platform technology
Exploring the synergism of PPAR-Y agonist and HDAC inhibitor for reversal of Alzheimers type of dementia and developing their brain targeted nano-carrier system for effective treatment
This website uses cookies or similar technologies, to enhance your browsing experience.